Notice: Global Information Announces Listing on JASDAQ Standard Market of the Tokyo Stock Exchange

Cover Image
Market Research Report

Asia Pacific Biodefense Market By Product (Anthrax, Smallpox, Botulism, Radiation/nuclear, and Other Products), By Country, Industry Analysis and Forecast, 2020 - 2026

Published by KBV Research Product code 988204
Published Content info 68 Pages
Delivery time: 1-2 business days
Price
Back to Top
Asia Pacific Biodefense Market By Product (Anthrax, Smallpox, Botulism, Radiation/nuclear, and Other Products), By Country, Industry Analysis and Forecast, 2020 - 2026
Published: January 29, 2021 Content info: 68 Pages
Description

The Asia Pacific Biodefense Market would witness market growth of 7% CAGR during the forecast period (2020-2026).

Biodefense is considered as the steps taken to re-establish the biosecurity of a group of organisms that are confronting biological threats or infectious diseases. It refers to an efficient public health care system with robust disease surveillance and quick actions designed to manage biological threats, to prevent the spread of disease, and offer medical care. The rising threat of biological weapons & nuclear-armed ICBM, supportive governmental initiatives, and expansion in the naturally occurring outbreaks, are leading factors pushing the market growth. Although, low investment in R&D by the government in emerging and underdeveloped countries, is anticipated to hamper the development of the biodefense market during the forecast years.

The advancements in technology have encouraged the innovation of advanced biosensor technology that is able to check both pathogens and benign microorganisms. In addition, various agencies are striving to create multifunctional sensors. Biotechnology provides an opportunity for the development of efficient countermeasures to biological weapons. Development and manufacturing of vaccines are of utmost importance from a biosecurity outlook.

The biodefense market will witness developmental possibilities if the government undertakes constant preventive steps to ensure the safety of the population and the economy. As the governments invest in these current and future policy initiatives, the companies operating in the market will witness a significant push in their revenue streams, by understanding the existing biosecurity and biodefense policy.

Based on Product, the market is segmented into Anthrax, Smallpox, Botulism, Radiation/nuclear, and Other Products. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Xoma Corporation, Altimmune, Inc., Emergent BioSolutions, Inc., Dynavax Technologies Corporation, SIGA Technologies, Inc., Elusys Therapeutics, Inc., Ichor Holdings, Ltd., Cleveland BioLabs, Inc., Bavarian Nordic A/S and Alnylam Pharmaceuticals, Inc.

Scope of the Study

Market Segmentation:

By Product

  • Anthrax
  • Smallpox
  • Botulism
  • Radiation/nuclear,
  • Other Products

By Country

  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific

Companies Profiled

  • Xoma Corporation
  • Altimmune, Inc.
  • Emergent BioSolutions, Inc.
  • Dynavax Technologies Corporation
  • SIGA Technologies, Inc.
  • Elusys Therapeutics, Inc.
  • Ichor Holdings, Ltd.
  • Cleveland BioLabs, Inc.
  • Bavarian Nordic A/S
  • Alnylam Pharmaceuticals, Inc.

Unique Offerings from KBV Research

  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free
Table of Contents

Table of Contents

Chapter 1. Market Scope & Methodology

  • 1.1 Market Definition
  • 1.2 Objectives
  • 1.3 Market Scope
  • 1.4 Segmentation
    • 1.4.1 Asia Pacific Biodefense Market, by Product
    • 1.4.2 Asia Pacific Biodefense Market, by Country
  • 1.5 Methodology for the research

Chapter 2. Market Overview

  • 2.1 Introduction
    • 2.1.1 Overview
    • 2.1.2 Market Composition and Scenario
  • 2.2 Key Factors Impacting the Market
    • 2.2.1 Market Drivers
    • 2.2.2 Market Restraints

Chapter 3. Competition Analysis - Global

  • 3.1 Recent Industry Wide Strategic Developments
    • 3.1.1 Partnerships, Collaborations and Agreements
    • 3.1.2 Approvals
    • 3.1.3 Acquisition and Mergers
  • 3.2 Top Winning Strategies
    • 3.2.1 Key Leading Strategies: Percentage Distribution (2016-2020)
    • 3.2.2 Key Strategic Move: (Partnerships, Collaborations, and Agreements : 2017, Jul - 2020, Jul) Leading Players

Chapter 4. Asia Pacific Biodefense Market by Product

  • 4.1 Asia Pacific Anthrax Market by Country
  • 4.2 Asia Pacific Smallpox Market by Country
  • 4.3 Asia Pacific Botulism Market by Country
  • 4.4 Asia Pacific Radiation/nuclear Market by Country
  • 4.5 Asia Pacific Other Product Market by Country

Chapter 5. Asia Pacific Biodefense Market by Country

  • 5.1 China Biodefense Market
    • 5.1.1 China Biodefense Market by Product
  • 5.2 Japan Biodefense Market
    • 5.2.1 Japan Biodefense Market by Product
  • 5.3 India Biodefense Market
    • 5.3.1 India Biodefense Market by Product
  • 5.4 South Korea Biodefense Market
    • 5.4.1 South Korea Biodefense Market by Product
  • 5.5 Singapore Biodefense Market
    • 5.5.1 Singapore Biodefense Market by Product
  • 5.6 Malaysia Biodefense Market
    • 5.6.1 Malaysia Biodefense Market by Product
  • 5.7 Rest of Asia Pacific Biodefense Market
    • 5.7.1 Rest of Asia Pacific Biodefense Market by Product

Chapter 6. Company Profiles

  • 6.1 Xoma Corporation
    • 6.1.1 Company Overview
    • 6.1.2 Financial Analysis
    • 6.1.3 Regional Analysis
    • 6.1.4 Research & Development Expense
  • 6.2 Altimmune, Inc.
    • 6.2.1 Company Overview
    • 6.2.2 Financial Analysis
    • 6.2.3 Research & Development Expense
    • 6.2.4 Recent strategies and developments:
      • 6.2.4.1 Acquisition and Mergers:
      • 6.2.4.2 Partnerships, Collaborations, and Agreements:
  • 6.3 Emergent BioSolutions, Inc.
    • 6.3.1 Company Overview
    • 6.3.2 Financial Analysis
    • 6.3.3 Research & Development Expense
    • 6.3.4 Recent strategies and developments:
      • 6.3.4.1 Acquisition and Mergers:
      • 6.3.4.2 Partnerships, Collaborations, and Agreements:
  • 6.4 Dynavax Technologies Corporation
    • 6.4.1 Company Overview
    • 6.4.2 Financial Analysis
    • 6.4.3 Research & Development Expense
  • 6.5 SIGA Technologies, Inc.
    • 6.5.1 Company Overview
    • 6.5.2 Financial Analysis
    • 6.5.3 Research & Development Expense
    • 6.5.4 Recent strategies and developments:
      • 6.5.4.1 Partnerships, Collaborations, and Agreements:
      • 6.5.4.2 Approvals:
  • 6.6 Elusys Therapeutics, Inc.
    • 6.6.1 Company Overview
    • 6.6.2 Recent strategies and developments:
      • 6.6.2.1 Approvals:
  • 6.7 Ichor Holdings, Ltd.
    • 6.7.1 Company Overview
    • 6.7.2 Financial Analysis
    • 6.7.3 Regional Analysis
    • 6.7.4 Research & Development Expense
    • 6.7.5 Recent strategies and developments:
      • 6.7.5.1 Partnerships, Collaborations, and Agreements:
  • 6.8 Cleveland BioLabs, Inc.
    • 6.8.1 Company Overview
    • 6.8.2 Financial Analysis
    • 6.8.3 Research & Development Expense
    • 6.8.4 Recent strategies and developments:
      • 6.8.4.1 Partnerships, Collaborations, and Agreements:
  • 6.9 Bavarian Nordic A/S
    • 6.9.1 Company Overview
    • 6.9.2 Financial Analysis
    • 6.9.3 Regional Analysis
    • 6.9.4 Research & Development Expense
    • 6.9.5 Recent strategies and developments:
      • 6.9.5.1 Partnerships, Collaborations, and Agreements:
      • 6.9.5.2 Approvals:
  • 6.10. Alnylam Pharmaceuticals, Inc.
    • 6.10.1 Company Overview
    • 6.10.2 Financial Analysis
    • 6.10.3 Research & Development Expense

LIST OF TABLES

  • TABLE 1 Asia Pacific Biodefense Market, 2016 - 2019, USD Million
  • TABLE 2 Asia Pacific Biodefense Market, 2020 - 2026, USD Million
  • TABLE 3 Partnerships, Collaborations and Agreements- Biodefense Market
  • TABLE 4 Approvals- Biodefense Market
  • TABLE 5 Acquisition and Mergers- Biodefense Market
  • TABLE 6 Asia Pacific Biodefense Market by Product, 2016 - 2019, USD Million
  • TABLE 7 Asia Pacific Biodefense Market by Product, 2020 - 2026, USD Million
  • TABLE 8 Asia Pacific Anthrax Market by Country, 2016 - 2019, USD Million
  • TABLE 9 Asia Pacific Anthrax Market by Country, 2020 - 2026, USD Million
  • TABLE 10 Asia Pacific Smallpox Market by Country, 2016 - 2019, USD Million
  • TABLE 11 Asia Pacific Smallpox Market by Country, 2020 - 2026, USD Million
  • TABLE 12 Asia Pacific Botulism Market by Country, 2016 - 2019, USD Million
  • TABLE 13 Asia Pacific Botulism Market by Country, 2020 - 2026, USD Million
  • TABLE 14 Asia Pacific Radiation/nuclear Market by Country, 2016 - 2019, USD Million
  • TABLE 15 Asia Pacific Radiation/nuclear Market by Country, 2020 - 2026, USD Million
  • TABLE 16 Asia Pacific Other Product Market by Country, 2016 - 2019, USD Million
  • TABLE 17 Asia Pacific Other Product Market by Country, 2020 - 2026, USD Million
  • TABLE 18 Asia Pacific Biodefense Market by Country, 2016 - 2019, USD Million
  • TABLE 19 Asia Pacific Biodefense Market by Country, 2020 - 2026, USD Million
  • TABLE 20 China Biodefense Market, 2016 - 2019, USD Million
  • TABLE 21 China Biodefense Market, 2020 - 2026, USD Million
  • TABLE 22 China Biodefense Market by Product, 2016 - 2019, USD Million
  • TABLE 23 China Biodefense Market by Product, 2020 - 2026, USD Million
  • TABLE 24 Japan Biodefense Market, 2016 - 2019, USD Million
  • TABLE 25 Japan Biodefense Market, 2020 - 2026, USD Million
  • TABLE 26 Japan Biodefense Market by Product, 2016 - 2019, USD Million
  • TABLE 27 Japan Biodefense Market by Product, 2020 - 2026, USD Million
  • TABLE 28 India Biodefense Market, 2016 - 2019, USD Million
  • TABLE 29 India Biodefense Market, 2020 - 2026, USD Million
  • TABLE 30 India Biodefense Market by Product, 2016 - 2019, USD Million
  • TABLE 31 India Biodefense Market by Product, 2020 - 2026, USD Million
  • TABLE 32 South Korea Biodefense Market, 2016 - 2019, USD Million
  • TABLE 33 South Korea Biodefense Market, 2020 - 2026, USD Million
  • TABLE 34 South Korea Biodefense Market by Product, 2016 - 2019, USD Million
  • TABLE 35 South Korea Biodefense Market by Product, 2020 - 2026, USD Million
  • TABLE 36 Singapore Biodefense Market, 2016 - 2019, USD Million
  • TABLE 37 Singapore Biodefense Market, 2020 - 2026, USD Million
  • TABLE 38 Singapore Biodefense Market by Product, 2016 - 2019, USD Million
  • TABLE 39 Singapore Biodefense Market by Product, 2020 - 2026, USD Million
  • TABLE 40 Malaysia Biodefense Market, 2016 - 2019, USD Million
  • TABLE 41 Malaysia Biodefense Market, 2020 - 2026, USD Million
  • TABLE 42 Malaysia Biodefense Market by Product, 2016 - 2019, USD Million
  • TABLE 43 Malaysia Biodefense Market by Product, 2020 - 2026, USD Million
  • TABLE 44 Rest of Asia Pacific Biodefense Market, 2016 - 2019, USD Million
  • TABLE 45 Rest of Asia Pacific Biodefense Market, 2020 - 2026, USD Million
  • TABLE 46 Rest of Asia Pacific Biodefense Market by Product, 2016 - 2019, USD Million
  • TABLE 47 Rest of Asia Pacific Biodefense Market by Product, 2020 - 2026, USD Million
  • TABLE 48 Key Information -Xoma Corporation
  • TABLE 49 Key Information - Altimmune, Inc.
  • TABLE 50 Key Information - Emergent BioSolutions, Inc.
  • TABLE 51 Key Information - Dynavax Technologies Corporation
  • TABLE 52 Key Information - SIGA Technologies, Inc.
  • TABLE 53 key information - Elusys Therapeutics, Inc.
  • TABLE 54 key Information - Ichor Holdings, Ltd.
  • TABLE 55 Key Information - Cleveland BioLabs, Inc.
  • TABLE 56 key information - Bavarian Nordic A/S
  • TABLE 57 Key Information - Alnylam Pharmaceuticals, Inc.

List of Figures

  • FIG 1 Methodology for the research
  • FIG 2 Key Leading Strategies: Percentage Distribution (2016-2020)
  • FIG 3 Key Strategic Move: (Partnerships, Collaborations, and Agreements : 2017, Jul - 2020, Jul) Leading Players
  • FIG 4 Recent strategies and developments: Altimmune, Inc.
  • FIG 5 Recent strategies and developments: Emergent BioSolutions, Inc.
Back to Top